Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001493152-24-050214
Filing Date
2024-12-16
Accepted
2024-12-16 16:05:35
Documents
65
Period of Report
2024-10-31

Document Format Files

Seq Description Document Type Size
1 form10-q.htm   iXBRL 10-Q 1083430
2 ex31-1.htm EX-31.1 17252
3 ex31-2.htm EX-31.2 17309
4 ex32-1.htm EX-32.1 6938
5 ex32-2.htm EX-32.2 6740
  Complete submission text file 0001493152-24-050214.txt   6004239

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE bctx-20241031.xsd EX-101.SCH 39556
7 XBRL CALCULATION FILE bctx-20241031_cal.xml EX-101.CAL 41826
8 XBRL DEFINITION FILE bctx-20241031_def.xml EX-101.DEF 236749
9 XBRL LABEL FILE bctx-20241031_lab.xml EX-101.LAB 319176
10 XBRL PRESENTATION FILE bctx-20241031_pre.xml EX-101.PRE 285530
68 EXTRACTED XBRL INSTANCE DOCUMENT form10-q_htm.xml XML 1130652
Mailing Address 3RD FLOOR, BELLEVUE CENTRE, 235-15TH STR WEST VANCOUVER A1 V7T 2X1
Business Address 3RD FLOOR, BELLEVUE CENTRE, 235-15TH STR WEST VANCOUVER A1 V7T 2X1 (604) 921-1810
BriaCell Therapeutics Corp. (Filer) CIK: 0001610820 (see all company filings)

EIN.: 000000000 | State of Incorp.: A1 | Fiscal Year End: 0731
Type: 10-Q | Act: 34 | File No.: 001-40101 | Film No.: 241551821
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)